This fixed-dose combination is used in situations involving certain distressing symptoms common to acute illness, and may help ease the overall symptom burden when symptoms intensify temporarily.

The combination of an analgesic, antipyretic, and antihistamine is commonly used to help manage symptom clusters that may become intense or disruptive during viral illnesses such as the common cold or flu. This preparation is relevant in conditions characterized by periods of heightened symptoms, and is applied in addressing symptoms related to physical discomfort like headache, muscle aches, and elevated body temperature (fever), alongside relief for upper respiratory manifestations such as sneezing, runny nose, and watery eyes.

Managing Systemic Aches and Sleep Disruption

This medication is commonly used when short-term symptomatic assistance is needed in two primary areas: managing symptoms related to physical discomfort and mitigating symptoms that interfere with daily functioning. By easing these challenging nocturnal manifestations, it provides short-term symptomatic assistance that helps maintain a sense of stability and supports the ability to obtain essential rest.

Quick Fact: Relief for Symptoms that Interfere with Rest

Regulatory References

1. DailyMed official drug label overview

The eligibility for Tapsin Nocturno is strictly defined by regulatory documents, focusing on patient age, coexisting medical conditions, and concurrent drug use. Use is explicitly prohibited (contraindicated) for patients with a known allergy to its components, those with severe hepatic impairment (severe liver disease), or individuals concurrently taking Monoamine Oxidase Inhibitors (MAOIs) or any other drug containing Acetaminophen.

Conditional use requires consulting a health professional for individuals with conditions such as glaucoma, enlarged prostate gland (trouble urinating), heart disease or hypertension, or asthma. Use is not recommended during pregnancy or lactation unless considered essential and prescribed by a physician. Furthermore, regulatory labels prohibit use for individuals who consume 3 or more alcoholic drinks daily.

Interactions with other medicines and products

Official regulatory documentation establishes several critical constraints and prohibitions for this fixed-dose combination.

Contraindicated Combinations and Restrictions

Co-administration is strictly prohibited with two categories of substances. First, the medicine must not be used alongside any other product containing Acetaminophen (prescription or nonprescription) to prevent exceeding safe dose limits. Second, it is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including for up to 14 days after MAOI therapy has ceased, due to the risk of potentiating the effects of Chlorphenamine.

Pharmacodynamic and Exposure Interactions

The presence of Chlorphenamine causes additive CNS depression when the medicine is taken with alcohol or other Central Nervous System (CNS) Depressants (e.g., tranquilizers or sedatives). The Acetaminophen component carries an explicit Liver Warning: consuming three or more alcoholic drinks daily significantly increases the risk of severe liver damage, a risk that is heightened in individuals with pre-existing liver disease.

Furthermore, Acetaminophen may increase the anticoagulant effects of medicines like Warfarin, a pharmacokinetic interaction noted in official labeling. Regulatory documents also note that children and the elderly are more susceptible to the neurological anticholinergic effects of Chlorphenamine.

Tapsin Nocturno's active component is an allosteric positive modulator that targets the gamma-aminobutyric acid type A ( GABA A) receptor complex in the central nervous system. This molecular interaction occurs at the benzodiazepine recognition site, which is located at the interface of the alpha and gamma subunits. The compound exhibits preferential, but not exclusive, binding to receptors containing the alpha1 subunit. The binding of the compound to the GABA A receptor facilitates the action of the endogenous inhibitory neurotransmitter, GABA, thereby potentiating the receptor's function. This potentiation increases the frequency of chloride ion channel opening, resulting in a greater influx of negatively charged chloride ions ( Cl^-) into the postsynaptic neuron. The increased Cl^- influx causes hyperpolarization of the neuronal membrane, which decreases the neuron's excitability and reduces the likelihood of generating an action potential. The intracellular consequence is a generalized inhibition of neuronal activity across various brain regions. This broad modulation of the central nervous system's inhibitory pathway leads to a systemic decrease in cerebral arousal and resultant sedation.

Administration Route and Form

Tapsin Nocturno is supplied as an oral tablet for adult use, with each unit containing 500 milligrams (mg) of Paracetamol (Acetaminophen) and 2 mg of Chlorphenamine. The approved route of administration for this fixed-dose combination product is swallowing the tablet with liquid. This form is intended to deliver the active components systemically for relief and requires no preparation beyond obtaining a glass of liquid.

Standard Dosing Regimen and Frequency

The established adult dosing regimen is the intake of one to two tablets as a single administration. The required frequency is once daily, with the explicit procedural condition that the dose must be taken before bedtime (antes de acostarse). The maximum dose is not to be exceeded in a 24-hour period.

Procedural Instructions and Use Constraints

To adhere to the labeled instructions, the prescribed dose must be swallowed whole with a glass of water or other liquid. The medication is designated for short-term use only, which aligns with the symptomatic relief of acute conditions. The product must not be administered to individuals with severe hepatic (liver) or renal (kidney) disease. The entire procedure is structured as a brief treatment course taken nightly to correspond with the inclusion of the sedating antihistamine.

Research evidence / Overview of studies for Tapsin Nocturno

The clinical evidence for Tapsin Nocturno is drawn from research on fixed-dose combination medicines that include an analgesic (like Acetaminophen) and a sedating antihistamine (like Chlorphenamine). This research has explored its role in symptomatic management, based on patterns observed in studies.

Evidence for Symptomatic Relief of Common Cold and Flu-Like Syndrome

This section summarizes the structure of Randomized Controlled Trials (RCTs) and meta-analyses that have explored the combination in the context of multiple symptoms associated with the common cold, such as headache, fever, and minor aches.

Research examined its application in conditions involving periods of heightened symptoms, specifically those of the acute common cold. Studies explored outcomes related to physical discomfort, monitoring patient-reported outcomes describing perceived discomfort related to fever, headache, muscle aches, and the overall severity of symptoms. Findings describe patterns observed in the studies related to measurements of overall scores compared to placebo. The evidence describes severity and duration for outcomes related to physical discomfort following study administration, based on patient diaries and clinical observation.

Research exploring short-term symptom changes contributes to the broader evidence landscape but has several limitations. The follow-up durations were limited, typically covering only a few days, and long-term effects are not fully established. Also, while overall symptom scores were examined, data show patterns related to measured changes for specific individual symptoms inconsistently across studies.

Evidence for Managing Cold Symptoms That Disrupt Sleep

This section will outline the available research concerning the "Nocturno" formulation, focusing on studies that have examined the combination's components and their role in outcomes related to functional imbalance and sleep parameters in adults.

Studies report how symptoms evolved in the observed populations, particularly focusing on the measurement of nocturnal discomfort that was associated with difficulty sleeping. Research highlights changes measured during the study period for both the intensity of the symptoms themselves and the resulting sleep measurements. Evidence contributes to understanding symptom patterns by supporting the rationale for including the sedating component in conditions associated with acute or disruptive episodes at night.

Evidence is limited for dedicated, large-scale RCTs that specifically designate sleep quality as the primary outcome for this fixed-dose combination. The data largely reflect the established pharmacological profile of the antihistamine compound. Comparative evidence is lacking to fully understand outcomes against non-sedating symptom relief options.

Research Gaps and Areas of Scientific Uncertainty

Several areas of uncertainty exist within the evidence landscape. Sample sizes were modest in some of the individual trials contributing to pooled data. Furthermore, while the combination was studied for measurements of overall symptom scores, specific subgroup findings are uncertain, and comparative evidence is lacking between this exact two-component preparation and other fixed-dose combinations. The general research provides context but not individual predictions, and long-term effects are not fully established.

Key Studies & References

1. Label: COLD AND FLU HBP- acetaminophen, chlorpheniramine maleate tablet, film coated (DailyMed/FDA)
2. Prevention and treatment of the common cold: making sense of the evidence (CMAJ, 2014)

Common questions about Tapsin Nocturno (FAQ)

Q: Does Tapsin Nocturno cause morning drowsiness or grogginess?

Official product information notes that the antihistamine component, Chlorphenamine, can have an extended presence in the body. Its elimination half-life, which describes how long the drug remains in the body, is described as ranging from roughly 14 to over 40 hours. This longer duration indicates the potential for residual effects like morning drowsiness or grogginess.

Q: Is Tapsin Nocturno only for people who can't sleep due to pain?

According to official documentation, the medication is intended for temporary relief from multiple cold and flu symptoms that disrupt rest. These symptoms can include minor aches, headache, fever, runny nose, and sneezing. Its use is described in the context of general symptom relief associated with colds, not solely restricted to discomfort related to pain.

Q: Can Tapsin Nocturno be taken if I am only experiencing a mild headache?

Official sources describe the product's use for symptoms such as minor aches and headache associated with the common cold. The regulatory label does not include an explicit statement concerning the necessary severity of symptoms for use. The overall purpose, however, is to address discomfort that interferes with sleep.

Q: Can Tapsin Nocturno be used to help with general difficulty falling asleep?

Official product uses describe the antihistamine component as contributing to the product's function as a nighttime sleep aid. This effect is described in the context of providing relief when cold or allergy symptoms are the cause of sleep difficulty.

Q: What happens if I accidentally take Tapsin Nocturno during the daytime?

Regulatory warnings state that the medication is very likely to cause drowsiness and dizziness. Official regulatory warnings state that activities requiring mental alertness, such as driving or operating machinery, should be avoided until an individual knows how the medication affects them. The product is specifically intended for use before bedtime.

Q: If I am taking an antidepressant, is there a concern about using Tapsin Nocturno?

Official warnings strictly prohibit the use of this medicine with any prescription Monoamine Oxidase Inhibitor (MAOI). This restriction applies to MAOIs used for depression, other psychiatric conditions, or Parkinson's disease. Regulatory labeling specifies that use is contraindicated for 14 days following the cessation of MAOI therapy.

Q: What kind of pain is Tapsin Nocturno intended to help relieve at night?

Official labeling describes the product's analgesic (pain-relieving) function as being for the temporary relief of minor aches and pains, including headache. This purpose is outlined specifically in the context of discomfort that accompanies the common cold.

Q: Can I use Tapsin Nocturno if I am currently taking other non-prescription pain relievers?

The primary restriction in the official warnings is the strict prohibition of co-administering this product with any other medicine containing Acetaminophen. Regulatory warnings state that this prohibition applies to any other medicine containing Acetaminophen, regardless of whether it is prescription or nonprescription. The purpose is to prevent exceeding safe dose limits for Acetaminophen.

Q: If I feel better after a single use, is it necessary to continue using Tapsin Nocturno?

The product is officially designated for the temporary relief of symptoms associated with acute conditions. Its use is generally guided by the presence of these disruptive symptoms.

Q: What is the reasoning behind the recommended minimum age for using Tapsin Nocturno?

Health authorities cite several reasons for age restrictions, including a lack of evidence supporting effectiveness in younger children. Concerns over potential misuse, overdose reports, and the possibility of rare serious side effects also serve as the regulatory basis for setting minimum age limits.

Q: Can Tapsin Nocturno be used for pain not associated with cold or flu?

Official regulatory text describes the use of the product for symptoms associated with hay fever, other upper respiratory allergies, and the common cold. Its indicated use is therefore tied to these specific conditions.

Q: How quickly does Tapsin Nocturno usually start working?

Official regulatory information notes that the antihistamine component, Chlorphenamine, typically begins to take effect within approximately two hours. The Acetaminophen component, which relieves pain and fever, often has a quicker onset of action.

Q: How long can the effects of Tapsin Nocturno last?

Official regulatory information notes that the effects of the antihistamine component, Chlorphenamine, are generally observed to last for about 4–6 hours. This duration guides the once-daily use before bedtime.

Q: Are there any known issues with taking Tapsin Nocturno and drinking coffee later?

Official regulatory text cautions that the use of the antihistamine component with other central nervous system stimulants, such as caffeine, may increase the risk of adverse effects. These effects can include increased nervousness or heart rate.

Q: Is it okay to take Tapsin Nocturno if I have a sensitive stomach?

Official product documents list common side effects including stomach upset and nausea.

Q: Does taking Tapsin Nocturno affect blood pressure levels?

Official information notes that the antihistamine component may infrequently cause cardiovascular adverse effects, which can involve changes in blood pressure. These effects are described as potentially including both low blood pressure (hypotension) and high blood pressure (hypertension).

Q: Is there a maximum number of nights in a row that Tapsin Nocturno can be used?

The product is labeled for short-term use only, and its purpose is for temporary relief of acute symptoms. Regulatory guidance generally describes when symptoms or fever persist or worsen after a few days of use, which may indicate a need for professional follow-up.

Q: Why do official sources sometimes state a drug is not for children under a certain age?

Health authorities cite several reasons for age restrictions, including limited evidence of effectiveness in the youngest age groups. Concerns over potential misuse, accidental overdose, and the risk of rare but serious side effects also serve as the regulatory basis for setting minimum age limits.

Q: Does the drug have specific warnings about driving or operating machinery?

Official regulatory warnings state that activities requiring mental alertness, such as driving or operating heavy machinery, should be avoided until an individual knows how the medication affects them. This caution is due to the potential for the product to cause dizziness or drowsiness.

Q: Is Tapsin Nocturno known to cause changes in appetite?

Loss of appetite, which is medically known as anorexia, is listed as a potential side effect of the antihistamine component, Chlorphenamine, in official product information.

Q: Can people with diabetes use Tapsin Nocturno without issue?

Official regulatory information advises caution when using medicines that may interfere with blood glucose (sugar) metabolism in individuals with diabetes. These effects could include hyperglycemia, or elevated blood sugar, and close monitoring of blood glucose levels is generally noted in this context.

Q: Are there any genetic considerations mentioned in official documents for using Tapsin Nocturno?

Research in regulatory-adjacent sources indicates that genetic variability may influence how the body processes the Chlorphenamine component. Differences in a specific liver enzyme called CYP2D6 can be a factor in the overall pharmacokinetics (how the body handles the drug) and the individual response.

Official Storage and Disposal Requirements

The required storage conditions for Tapsin Nocturno are defined by regulatory labeling to maintain the product's stability. The medicine must be stored at a temperature no greater than 25 C and requires explicit protection from heat, light, and humidity.

The tablets must remain in their original container at all times. As a mandatory safety precaution, the product must be kept out of the sight and reach of children.

Disposal instructions mandate that any unused or expired product be discarded in accordance with applicable local regulations for pharmaceutical waste, which typically involves collection points or specific procedures to prevent improper disposal.